169 related articles for article (PubMed ID: 26598487)
21. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.
Lee SJ; Jeong YI; Park HK; Kang DH; Oh JS; Lee SG; Lee HC
Int J Nanomedicine; 2015; 10():5489-503. PubMed ID: 26357473
[TBL] [Abstract][Full Text] [Related]
22. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
[TBL] [Abstract][Full Text] [Related]
23. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
24. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
26. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
27. Matrix Metalloproteinase-sensitive Multistage Nanogels Promote Drug Transport in 3D Tumor Model.
Nagel G; Sousa-Herves A; Wedepohl S; Calderón M
Theranostics; 2020; 10(1):91-108. PubMed ID: 31903108
[TBL] [Abstract][Full Text] [Related]
28. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
[TBL] [Abstract][Full Text] [Related]
29. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy.
She W; Li N; Luo K; Guo C; Wang G; Geng Y; Gu Z
Biomaterials; 2013 Mar; 34(9):2252-64. PubMed ID: 23298778
[TBL] [Abstract][Full Text] [Related]
30. Zwitterionic nanoparticles constructed with well-defined reduction-responsive shell and pH-sensitive core for "spatiotemporally pinpointed" drug delivery.
Huang P; Liu J; Wang W; Li C; Zhou J; Wang X; Deng L; Kong D; Liu J; Dong A
ACS Appl Mater Interfaces; 2014 Aug; 6(16):14631-43. PubMed ID: 25100635
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
[TBL] [Abstract][Full Text] [Related]
32. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
33. A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan.
Cun X; Ruan S; Chen J; Zhang L; Li J; He Q; Gao H
Acta Biomater; 2016 Feb; 31():186-196. PubMed ID: 26675124
[TBL] [Abstract][Full Text] [Related]
34. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy.
Wu G; Wang Z; Bian X; Du X; Wei C
Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652
[TBL] [Abstract][Full Text] [Related]
35. IL-6 Antibody and RGD Peptide Conjugated Poly(amidoamine) Dendrimer for Targeted Drug Delivery of HeLa Cells.
Mekuria SL; Debele TA; Chou HY; Tsai HC
J Phys Chem B; 2016 Jan; 120(1):123-30. PubMed ID: 26670944
[TBL] [Abstract][Full Text] [Related]
36. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
37. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
[TBL] [Abstract][Full Text] [Related]
38. The anti-tumor efficiency of poly(L-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores.
Pu Y; Chang S; Yuan H; Wang G; He B; Gu Z
Biomaterials; 2013 May; 34(14):3658-66. PubMed ID: 23433775
[TBL] [Abstract][Full Text] [Related]
39. Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration.
Li HJ; Du JZ; Liu J; Du XJ; Shen S; Zhu YH; Wang X; Ye X; Nie S; Wang J
ACS Nano; 2016 Jul; 10(7):6753-61. PubMed ID: 27244096
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor drug delivery system based on cyclodextrin-containing pH-responsive star polymer: in vitro and in vivo evaluation.
Xiong Q; Zhang M; Zhang Z; Shen W; Liu L; Zhang Q
Int J Pharm; 2014 Oct; 474(1-2):232-40. PubMed ID: 25149124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
